Introduction:

From research and development to market launch, innovative drugs require a long cycle and significant investment, and their commercial value heavily depends on intellectual property protection. In overseas transactions, the quality of IP assets directly determines pricing, bargaining chips, and subsequent market competitiveness.

For overseas pharmaceutical companies, intellectual property management should not passively wait for buyers to arrive, but should proactively advance during the transaction preparation stage. This article systematically reviews the intellectual property issues that must be addressed in innovative drug overseas BD→ from the perspective of buyer due diligence patent layout strategies→ FTO risk investigation→ and contract clause targeting.

1. Clarifying IP Due Diligence: What Are Overseas Buyers Looking At?

During intellectual property due diligence, overseas buyers conduct a comprehensive review of the target asset starting from six core issues:

• Is the disposal right complete—Do domestic pharmaceutical companies have full disposal rights over the assets to be traded? Are there disputes or potential disputes among co-owners, ownership, or potential disputes?
• Is patent coverage sufficient—can the relevant patents cover candidate drugs, indications, formulations, processes, uses, combination therapies, and future commercialization plans?
• Is the core market layout in place—are there gaps in patent layouts in key markets such as the United States, Europe, and Japan?
• Is the patent protection period sufficient—can the patent period cover the main commercialization cycle? Has the patent term compensation system been utilized?
• Is FTO risk controllable—will third-party patents be infringed during overseas R&D, production, and sales?
• Who bears risk liability—how is liability allocated in case of ownership disputes, infringement lawsuits, or patent invalidity?

The results of due diligence on these issues directly affect transaction arrangements. Rights flaws may lead to delivery delays, lack of patent layout may lower down payments, and higher FTO risks may require market area reduction. If the risk cannot be reasonably explained, the buyer may even abandon the transaction.
Domestic pharmaceutical companies should conduct systematic and thorough intellectual property self-inspections of the assets to be traded as soon as possible. The earlier IP checks are initiated, the more time companies have to resolve historical legacy issues and gain the upper hand in subsequent transaction negotiations. Conversely, if problems are only discovered when the Term Sheet is signed and the buyer officially initiates due diligence, domestic pharmaceutical companies will be at a disadvantage. Even if remedial measures exist, they will pay higher costs due to tight time and sharply increased negotiation pressure.

2. Patent Layout: Building a Cross-Border Commercial Moat

In overseas transactions for innovative drugs, overseas buyers truly examine the depth of patent deployment in target markets, the coverage of claims for core products, the commercial value of remaining protection periods, and the defense thickness of peripheral patents.
(1) Core patents + peripheral patents: layered barriers
For small molecule drugs, compound patents are undoubtedly high-value foundational assets, but relying on a single patent alone is difficult to withstand complex and ever-changing market risks. Peripheral patents such as crystal form, salt form, formulation, synthesis route, impurity control, dosage regimen, and combination drugs also determine the product’s lifecycle.
For emerging therapies such as antibodies, ADCs (antibody-drug conjugates), and nucleic acid drugs, the patent layout is more layered and complex. Antibody drugs must comprehensively cover sequences, epitopes, functional characteristics, and purification processes; ADC drugs must precisely lock on the linker, load, coupling method, and DAR (drug-to-body ratio) range; Nucleic acid drugs need to be treated around chemical modification, delivery systems, and targeted tissues.

A mature patent portfolio must anchor itself with final commercialization as its anchor point, with layers of defense in four areas:

• First, the core patents protect the molecule itself
• Second, use peripheral patents to compress competitors’ maneuvering space
• Third, extend the lifecycle through process and formulation patents
• 4. Supporting subsequent clinical expansion through patents for applications and combination therapies.

These four layers are presented to the buyer, making the boundaries of commercial value naturally clear and discernible.
(2) Patent term compensation + data protection
The domestic pharmaceutical intellectual property protection system has been continuously improved in recent years, providing strong support for innovative pharmaceutical companies.
The compensation system for drug patent rights terms has been fully implemented. For invention patents related to new drugs that have obtained marketing approval in China, compensation can be provided for the protection period actually occupied by clinical trials and administrative approvals. The scope of compensation covers patents for new drug products, preparation method patents, and patents for pharmaceutical use. This system can effectively extend the market exclusivity period of drugs, bringing sustained economic benefits to pharmaceutical companies.
The “Implementation Measures for Data Protection in Drug Trials” establishes a tiered data protection system:

• Innovative drugs: 6-year data protection period
• Improved new drug: 4 years
• First generic drug: 3 years

During the data protection period, if other applicants apply for marketing based on protected data without the consent of the marketing authorization holder, the National Medical Products Administration will not grant approval.
Patent term compensation and data protection systems together form a dual barrier of “patent protection + data protection.” This not only significantly extends the market exclusivity period of products, but also enhances the company’s valuation bargaining power in BD transactions. For innovative drug companies going global, making good use of these systems helps them secure a more advantageous competitive position in the international market and attract more attention and cooperation from overseas buyers.
(3) Early Overseas Expansion
Some innovative pharmaceutical companies face serious lagging issues—often only discovering gaps in patent layout in key markets when clinical data is excellent and BD work begins, or even missing the legal deadline for priority or entering the national phase.
At the initial stage of the project, a comprehensive overseas patent layout plan should be formulated based on the target market’s patent regulations, market demand, and competitive landscape. If the transaction region is the US or Europe but patents are only located in China, or if the scope of overseas claims is much narrower than in China, buyers will find it difficult to be directly affected by global asset valuations, pricing, and success rates.
(4) Collaborative Protection

of Patents and Trade Secrets Not all technological achievements are suitable for protection through patents.

• For technical solutions that are easily reverse cracked or circumvented, applying for a patent is necessary because it allows the technology to be made public for legal protection and prevents unauthorized use.
• For technical achievements that are difficult to obtain externally, difficult to derive backward, and have long-term value, it is appropriate to adopt the method of protecting trade secrets.

However, it should be noted that the premise of protecting technical secrets is that the enterprise itself has taken reasonable confidentiality measures; otherwise, legal support cannot be obtained;
In BD transactions, the valuation of trade secrets is often lower than that of patents, stemming from their “unverifiability”—buyers cannot independently confirm the scope and protection strength of patents through public databases as they would with patent verification; At the same time, technical secrets cannot compete with independent third-party R&D or reverse engineering. Therefore, trade secrets are more suitable as supplements to patents rather than substitutes.
In practice, companies should sign strict confidentiality agreements with employees, partners, and others, clarifying confidentiality obligations and responsibilities, while rigorously managing documents and equipment involving technical secrets to prevent information leaks. Through the coordinated protection of patents and trade secrets, companies can more comprehensively safeguard their technological achievements and enhance their competitive edge in the market.

3. FTO Free Implementation Analysis

Patent rights ≠ can be freely implemented.
Especially in the pharmaceutical field, even if a technical solution is patented, it may still be subject to third-party prior patents. The goal of FTO (Freedom to Operate) analysis is to identify, assess, and respond to such infringement risks in advance.
In recent years, platform technologies, delivery systems, and process patents have become high-risk areas for FTO (Export Organization) risks:
from targets, molecular structures, antibody sequences, carriers, delivery systems, linkers, payloads, formulations, production processes, detection methods to indications, every link may involve third-party patents. Even if the core molecular system is developed independently, if third-party delivery systems, expression systems, coupling technologies, or purification methods are used during R&D or commercialization, infringement lawsuits may still occur in the target market.

High-risk areas for FTO are mainly concentrated in technology-intensive areas of core markets. Core markets have high patent density and rapid technological iteration. If companies lack sufficient understanding of the local patent environment, they are easily caught up in infringement disputes. For emerging markets, enterprises should strengthen forward-looking research on patent layout, plan patent application strategies in advance based on local market demands and regulatory characteristics, and build a comprehensive patent protection network; In core markets, in-depth and detailed patent searches and analyses are required, with comprehensive reviews of product technical solutions to identify potential infringement risk points.
Companies should also establish a comprehensive FTO review mechanism, deploy related work from the initial stage of project initiation, and integrate FTO review throughout the entire product development process. By collaborating with professional intellectual property institutions and leveraging external expertise, the accuracy and efficiency of FTO reviews can be enhanced. For risks identified during the review, product technical solutions should be promptly adjusted or patent licensing or other solutions should be sought to ensure free implementation of products in target markets, effectively reducing FTO risks in overseas projects, and ensuring smooth progress of overseas market expansion strategies.

4. Intellectual Property Risk Clauses: Risks identified through due diligence must ultimately be implemented in contract terms.

(1) Statement of Warranty Clauses

In innovative drug overseas transactions, warranty clauses are an important part of contracts. Overseas buyers usually require domestic pharmaceutical companies to make explicit statements and guarantees regarding the clarity of intellectual property ownership, no infringement risks, and patent validity, for example: guaranteeing full ownership of the intellectual property assets to be traded and that there are no ownership disputes; Ensure that relevant patents cover all key technologies and future commercialization solutions of the drug, and are effective in the target market; Ensuring that production, sales, and other activities overseas do not infringe on third-party intellectual property rights.
When domestic pharmaceutical companies respond to such clauses, they need to carefully review their own intellectual property status to ensure their statements are true and accurate. If there are uncertainties, they should promptly communicate and negotiate with the buyer or seek professional assessment to avoid liability for breach of contract due to false statements. At the same time, pharmaceutical companies can also require buyers to make corresponding statements and guarantees regarding payment ability and transaction compliance to protect their own interests.
(2) Compensation Clauses

: Compensation clauses directly affect the distribution of interests between both parties after intellectual property risks occur. Buyers usually want the clauses to fully protect their interests and require the seller to bear full compensation for any losses caused by intellectual property issues, including direct and indirect losses such as reduced sales and litigation costs.
The seller should appropriately limit the compensation terms to reasonably control risk exposure, for example: setting a compensation limit and stipulating that the total compensation for intellectual property issues does not exceed a certain percentage of the transaction amount; Excluding liability for indirect losses, only for foreseeable direct losses; Clearly define the compensation conditions, such as requiring the buyer to promptly notify the seller and take reasonable measures to mitigate losses upon discovering intellectual property issues; otherwise, the seller may not bear or correspondingly reduce or exempt compensation liability. Through such restrictions, sellers can protect the buyer’s basic rights while avoiding excessive compensation burdens caused by uncontrollable risks.
(3) Patent Protection and Rights Protection Clauses

: Patent protection and rights protection clauses are crucial for safeguarding the patent rights of both parties in a transaction. Both parties should clearly agree on the obligations to maintain the patent, including annual fee payments and patent monitoring, which are usually the responsibility of the patent holder to ensure the validity of the patent.
When patent infringement occurs, the responsible party for rights protection, the method of bearing costs, and the plan for profit distribution should be clearly defined. If the domestic pharmaceutical company is the patent holder, it can be agreed that it will lead rights protection, the buyer will provide necessary support and assistance, and the costs and profits will be shared according to the agreed ratio; If the buyer has more resources in a specific market, it can also be agreed that the buyer is responsible for defending rights in that market. Both parties should also agree on the timeline and procedures for rights protection to ensure that timely and effective measures can be taken after discovering infringement, preventing further losses caused by delays.
(4) Pipeline Shelf Risk Prevention

Pipeline shelf risk refers to situations where, after obtaining the drug intellectual property, the buyer fails to actively develop and promote the drug in the target market, resulting in the drug being unable to commercialize in the target market and thus affecting the seller’s expected returns.
To prevent such risks, the contract should clearly state the buyer’s diligent development obligations. It can be agreed that the buyer must formulate and implement a detailed development plan within a certain period after acquiring the intellectual property, including advancing clinical research and progressing registration applications. If the buyer fails to fulfill development obligations on time, the seller has the right to demand liquidated damages or take other remedial measures, such as reclaiming part or all of the intellectual property. Sellers can also require buyers to regularly report development progress to stay informed about drug development trends in target markets, ensuring buyer behavior complies with contractual agreements, effectively reducing pipeline shelf risks, and protecting their own interests.
(5) Agreement on Ownershipof Improvement

Achievements In overseas transactions of innovative drugs, the ownership of subsequent improvement results is a controversial issue. Both parties should clearly agree in advance in the contract on the ownership of improvement results and related rights distribution.
If the intellectual property rights of the drug belong to the buyer, it can be agreed that the improvements made based on the drug also belong to the buyer, but the seller has the right to use or share in the benefits from the improvements under certain conditions; If both parties jointly own the intellectual property rights of the drug, the results of the improvements are generally shared by both parties, and the specific distribution of rights can be determined through negotiation based on the amount of their contributions. Both parties must also clarify the criteria for defining improvement results, as well as procedures for declaration, use, and transfer of these improvements. Through clear contract terms, disputes over the ownership of improvement results can be avoided, ensuring the stability of the cooperative relationship between both parties.

5. Summary

The essence of innovative drug overseas expansion is to place technological assets in the global market for testing.

Whether rights are clear, patent layout reasonable, FTO risks controllable, and contract terms comprehensive—these intellectual property issues directly determine whether transactions can proceed smoothly and realized expected value.

Intellectual property management is not an “add-on” to overseas transactions, but a “mandatory question” that determines success or failure. Proactive prevention and control starting from the transaction preparation stage is the only way to proceed steadily and long-term during the overseas journey.

This article is compiled based on publicly available information and industry practical experience, for reference only, and does not constitute legal advice.

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.